RxDoctor Payments Data

Katherine Hefner

Nurse Practitioner · Clyde, NCNPI 1477651206

Payments from drug & device makers

$7,617in general payments, 2019–2025

Across 363 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$917
  • Johnson & Johnson$902
  • Pfizer$781
  • Amgen$658
  • Merck$581
  • AstraZeneca$546
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$7,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,617 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$67,596
Medicare patients
653
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban432$357,961
EntrestoSacubitril/Valsartan107$108,606
XareltoRivaroxaban117$101,419
FarxigaDapagliflozin Propanediol94$68,302
Repatha SureclickEvolocumab94$58,665
JardianceEmpagliflozin27$31,275
Bumetanide48$3,723
Metoprolol Succinate331$3,322
Ranolazine ErRanolazine31$2,183
Potassium Chloride127$1,936
Diltiazem 24hr Er (Cd)Diltiazem Hcl137$1,933
Furosemide326$1,379
Digoxin94$1,376
Flecainide Acetate58$1,145
SotalolSotalol Hcl61$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$781$357,961432 claims
NovartisEntresto$303$108,606107 claims
Johnson & JohnsonXarelto$902$101,419117 claims
AstraZenecaFarxiga$546$68,30294 claims
Boehringer IngelheimJardiance$917$31,27527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Clyde

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →